Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posterior Reversible Encephalopathy Syndrome With Spinal Cord Involvement 2 Months After a Burn Injury.

Neurology·2022
Same author

Association of social network structure and physical function in patients with multiple sclerosis.

Neurology·2020
Same author

Ultrasound measurement of optic nerve sheath diameter pre- and post-lumbar puncture.

The ultrasound journal·2020
Same author

Relationship between subjective visual vertical and balance in individuals with multiple sclerosis.

Physiotherapy research international : the journal for researchers and clinicians in physical therapy·2018
Same author

Psychometric Properties of a Core Set of Measures of Balance for People With Cerebellar Ataxia Secondary to Multiple Sclerosis.

Archives of physical medicine and rehabilitation·2016
Same author

Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis.

Multiple sclerosis international·2013

Related Experiment Video

Updated: May 24, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Multiple sclerosis: pathogenesis and treatment.

Ingrid Loma1, Rock Heyman

  • 1Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.

Current Neuropharmacology
|March 2, 2012
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a central nervous system autoimmune disease causing inflammation. Current treatments aim to reduce inflammation in relapsing forms, but a cure remains elusive.

Keywords:
Multiple sclerosisglatiramer acetate.immune responseinterferon-betapathogenesis

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: May 24, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune demyelinating disease of the central nervous system.
  • Affecting approximately 400,000 people in the U.S., MS typically onset during young adulthood.
  • The relapsing-remitting form is the most common among the four clinical types.

Purpose of the Study:

  • To review the current understanding and management of Multiple Sclerosis.
  • To highlight the challenges in finding a cure due to unknown etiology.
  • To discuss FDA-approved agents for relapsing forms of MS and the lack of approved treatments for primary progressive MS.

Main Methods:

  • Review of current literature on Multiple Sclerosis.
  • Analysis of FDA-approved medications for MS treatment.
  • Discussion of ongoing clinical trials for new MS therapies.

Main Results:

  • Eight agents are FDA-approved to manage MS, primarily targeting immune system components to reduce inflammation.
  • Approved medications include various interferon-beta preparations, glatiramer acetate, mitoxantrone, natalizumab, and fingolimod.
  • No agents are currently FDA-approved for the primary progressive form of MS.

Conclusions:

  • Despite available treatments, the heterogeneity of MS, individual patient responses, and medication toxicities present ongoing challenges.
  • The unknown etiology of MS complicates the search for a definitive cure.
  • Further research and development of novel therapies are crucial for improving MS management.